Natera’s stock dropped 9.7% after the company lowered full-year revenue guidance by over $120 million and raised R&D spend by $50 million, signaling investor concerns over margin pressure and cautious outlook despite strong volume growth.

• Revenue for Q1 reached $697 million, a 39% year-over-year increase, driven by robust volume growth across women's health and oncology segments.
• Oncology volumes rose 55% year-over-year to 249,000 clinical units, setting a new quarterly record.
• The new Fetal Focus product is gaining traction rapidly with nearly 200,000 orders on an annualized run rate following a successful clinical trial (EXPAND).
• Gross margin for Q1 slightly exceeded original guidance at nearly 65%, but was negatively impacted by higher-than-normal samples in process, compressing margins by about 2 percentage points.
• Management raised full-year gross margin guidance slightly to 65% midpoint but increased R&D expense forecast by $50 million to accelerate clinical trials, reflecting a more cautious outlook on near-term profitability.